Intra-Cellular Therapies, Inc. ITCI
131.87 0.00 (+0.00%)
At closeApr 2, 2025, 4:00 PM EDT
131.87 Day range 131.87
52-week range unavailable
- YTD
- +57.89%
- 1 year
- +97.80%
News
benzinga.com The Year-End 2025 Biotech Rally And What It Means For 2026 
globenewswire.com Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA…
businesswire.com INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular…
businesswire.com ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share…
zacks.com ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
zacks.com Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.30 per share a year ago.
globenewswire.com Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million , representing a 51% increase over the same period in 2023
cnbc.com Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
prnewswire.com SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
zacks.com Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
zacks.com Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last? Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down…
businesswire.com INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular…
businesswire.com Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson &…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
https://thefly.com BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal Intra-Cellular +32.49 (+34.25%) Johnson & Johnson +2.22 (+1.56%)
zacks.com ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.
reuters.com Drugmakers rush to sign deals on first day of industry conference Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
benzinga.com Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday 
https://thefly.com Intra-Cellular just downgraded at Morgan Stanley, here's why Intra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%)
investopedia.com Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical company for roughly $14.6 billion.
businesswire.com ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
zacks.com Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains? Intra-Cellular (ITCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near…
reuters.com J&J to buy Intra-Cellular Therapies for $14.6 billion Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.
benzinga.com Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket 
benzinga.com Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio? Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United…
benzinga.com Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday 
benzinga.com Earnings Scheduled For February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
benzinga.com Earnings Scheduled For November 2, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
- benzinga.com Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 497 companies set new 52-week lows.
benzinga.com Earnings Scheduled For March 1, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.- benzinga.com Earnings Scheduled For November 3, 2022 Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
- benzinga.com Earnings Scheduled For August 9, 2022 Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 Upgrades
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 Upgrades
- benzinga.com Earnings Scheduled For May 10, 2022 Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 22, 2022 Upgrades
- benzinga.com Stocks That Hit 52-Week Highs On Thursday On Thursday, 75 stocks made new 52-week highs.
- benzinga.com The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution Here's a roundup of top developments in the biotech space over the last 24 hours:
- benzinga.com Earnings Scheduled For March 1, 2022 Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter.
- benzinga.com The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the…
- benzinga.com 53 Biggest Movers From Friday Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday.
- benzinga.com 34 Stocks Moving In Friday's Mid-Day Session Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday.
- benzinga.com 45 Biggest Movers From Yesterday Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55.
- benzinga.com 34 Stocks Moving In Tuesday's Mid-Day Session Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor…
- benzinga.com Earnings Scheduled For November 9, 2021 Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021